People: Veracyte Inc (VCYT.OQ)
24 Apr 2019
Dr. Fred E. Cohen, M.D. Ph.D. is Independent Director of the Company. He is a senior advisor to TPG where he served as a partner and founder of TPG Biotechnology, a life sciences focused investment effort from October 2001 to December 2016. From 1988 through December 2014, Dr. Cohen was an Adjunct Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. Dr. Cohen currently serves as a director of BioCryst Pharmaceuticals, Inc., CareDx, Inc., Five Prime Therapeutics, Inc., Genomic Health, Inc., Roka Bioscience, Inc. and Tandem Diabetes Care, Inc., and a number of privately held companies. In addition, Dr. Cohen served as a director of Quintiles Transnational Holdings Inc. from May 2007 until November 2015. Dr. Cohen holds a B.S. in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford University, where he was a Rhodes Scholar, and an M.D. from Stanford University.
|Total Annual Compensation, USD||52,494|
|Restricted Stock Awards, USD||10,000|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||38,356|
|Fiscal Year Total, USD||100,850|